Description: Dominari Holdings Inc. (f/k/a AIkido Pharma Inc.) until recently was focused primarily on the development of a diverse portfolio of small-molecule anticancer and antiviral therapeutics and related patent technology. In September 2022, the Company agreed to acquire a registered broker-dealer and transition its primary business operations to fintech and financial services. Upon the final closing of this acquisition, the Company's fintech and financial services business will be operated through its subsidiary, Dominari Financial Inc. The Company continues to develop its therapeutics and related patent technology, as well as other ventures, through its subsidiary, AIkido Labs, LLC.
Home Page: www.dominariholdings.com
DOMH Technical Analysis
725 5th Avenue
New York,
NY
10022
United States
Phone:
212-393-4540
Officers
| Name | Title |
|---|---|
| Mr. Anthony C. Hayes Esq. | CEO & Chairman |
| Mr. Kyle Michael Wool | President & Director |
| Ms. Soo J. Yu | Director & Special Projects Manager |
| Mr. Christopher Devall | Chief Operating Officer |
| Mr. Jaime Mercado Jr. | Chief Compliance Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2608 |
| Price-to-Sales TTM: | 0.8176 |
| IPO Date: | 1984-09-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |